Antipyretic TRIZ Cases

Conventional OA therapies may relieve symptoms without slowing progression; phytonutrients target synovitis and cartilage degradation.

Selective diamine derivatives inhibit LTA4 hydrolase, potentially lowering LTB4 production and downstream inflammation in chronic inflammatory diseases.

Citric, fumaric, and tartaric acid stabilizers protect Compound A formulations during storage while targeting KDM1A with reduced toxicity.

Controlled excipient ratios turn acetone-extracted gamboge resin into a tablet that releases drug over 12–72 hours while maintaining blood levels.

Hydrophobic chromatography separates clipped variants from intact activatable antibodies to improve composition purity, yield, and therapeutic safety.

Coupling allergen peptides with CTLA-4 or PD-1 on VLP surfaces aims to induce specific tolerance while limiting severe reactions from direct allergen dosing.

Isolate TRAMlo neutrophil and monocyte subsets to reduce inflammation and improve vascular integrity in atherosclerosis.

Methylcellulose and hyaluronan form a local depot that releases anesthetic for 48 hours to 5 days, reducing infusion and opioid reliance.

Chronic skin symptoms remain difficult to relieve; multi-extract herbal formulations combine plant-derived bioactives in creams, ointments, and juices.

An optimized glycyrrhizin dose in animal food targets atopic dermatitis, inhibiting IL-5 release without hypertension or kidney issues.

An oral Bifidobacterium longum RAPO composition targets inflammation and fibrosis through gut-lung axis immune modulation.

Current lupus treatments may miss BDCA2-linked immune dysfunction; this case uses targeted antibodies in a subcutaneous formulation.

Genetic polymorphisms guide CD30L inhibitor selection for Crohn’s disease and primary sclerosing cholangitis, targeting patients likely to benefit.

Racemic loxoprofen can limit pharmacological selectivity; separating chiral isomers identifies derivatives with stronger joint activity and lower dose needs.

Tumor-driven arginase lowers L-arginine and suppresses immunity; these compounds block the enzyme to restore immune responsiveness.

CO measurements are correlated with biomarkers to support accessible, non-invasive assessment of ASD, inflammation, and autoimmunity.

Stabilizers and surfactants protect anti-OX40 antibodies from denaturation, aggregation, and precipitation during handling, shipping, and storage.

Folic acid targets folate receptors while aminoclay stabilizes drug payloads, supporting selective delivery and reducing systemic exposure.

High-concentration anti-TNFα formulations use Fc substitutions and selected excipients to limit aggregation and support less frequent dosing.

Learn how Fc-containing multispecific antibodies block IL-4R and IL-31 while remaining stable above 100 mg/mL for subcutaneous injection.

Rabbit-derived IL-4R variable domains combine high-affinity binding and stability for multispecific antibodies blocking IL-4 and IL-13 signaling.

Pitcher plant herbal preparations adjust fibrinogen toward homeostatic levels while supporting fibroblast activity for inflammation and tissue repair.

Defined heavy- and light-chain CDRs target WARS1 selectively, limiting cross-reactivity with other aminoacyl-tRNA synthetases.

HPMC matrix and particle-size control help release acetone-extracted gamboge resin over 12–72 hours while maintaining drug levels.

Localized topical delivery combines cannabidiol, menthol, camphor, and herbal extracts to relieve pain and inflammation while avoiding systemic NSAID side effects.

Selective CDR grafting and framework residue retention help anti-C-MET antibodies preserve affinity while reducing immunogenicity.

Targeted antibodies bind SCF248 to block c-Kit interaction, reducing immune cell activation, chronic inflammation, and fibrosis.

Small-molecule Formula (I) compounds modulate TNF alpha activity while reducing cardiac toxicity linked to benzimidazole cores.

Extracted IL-6-binding domains with fatty acid substituents address antibody cost and immunogenicity while supporting oral dosing.

Separating the NSAID derivative from its solvent during storage preserves stability while enabling transdermal use and avoiding gastrointestinal reactions.

Ethanol extraction, enzymatic treatment, and purification isolate Saururus chinensis polysaccharides that support mucin and tight junctions in IBD.

Saffron targets ulcerative colitis inflammation by upregulating HO-1/GPx2, regulating immune cells, and maintaining gut microbiota balance.

Polymorphic and salt forms of AHR inhibitors address poor aqueous solubility and stability while preserving therapeutic activity.

This case targets MOSPD2, CD63, and integrin β2 interactions to address redundant chemokine pathways in inflammatory migration.

This case uses MMP12 levels for early diagnosis and MMP12 inhibition to address vascular complications linked to IL-6 treatment.

Water or ethanol extracts from Rubus idaeus stems and leaves reduce cytokines and Granzyme B while preserving anti-inflammatory balance.

This case uses a castor oil and gelling-agent matrix to limit burst release and sustain bupivacaine delivery for 72 hours.

Surfactants, cyclodextrins, or antioxidants help prevent decomposition and precipitation in water-based pharmaceutical compositions.

This case uses engineered CDR sequences and epitope targeting to neutralize IFN-γ, reduce inflammatory markers, and support T-cell immunity.

This case uses optimized antibody CDR sequences to target CD24, inhibit tumor growth, and suppress metastasis in preclinical models.

Histidine, arginine-HCl, sucrose, and polysorbate-80 stabilize concentrated TL1A antibodies while preserving at least 99% monomer.

This case uses localized molecular substituents to balance cell permeability, potency, and cardiac toxicity in TNF alpha modulation.

Humanized SCF248 antibodies block c-Kit signaling to reduce inflammation and fibrosis.

This case uses α4β7 integrin blockade to reduce biliary inflammation, lower alkaline phosphatase, and delay PSC progression.

Specific immunoglobulin heavy and light chains neutralize IL-36R activity for inflammatory skin disorders such as psoriasis.

Quantified biomarker panels and clinical adjustments address subjective RA assessment and support therapy response monitoring.

Tetrahydro-cyclopenta indene compounds selectively inhibit HIF-2α to improve treatment efficacy and reduce off-target toxicity.

Humanized or deimmunized antibodies block Gremlin-1/2 signaling, reducing inflammation and fibrosis while supporting cardiac function.

High-concentration anti-CXCR5 formulations use citrate, polysorbate 20, sucrose, and arginine to limit particles during storage.

When PD-1 blockade is limited by NKG2A upregulation, dual antibodies reactivate NK and CD8 T-cell cytotoxicity.